Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 10
Submit an article Journal homepage
181
Views
0
CrossRef citations to date
0
Altmetric
Correspondence

Additional chromosomal abnormalities at diagnosis or during tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia

Ahmet Emre EskazanDivision of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, TurkeyCorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0001-9568-0894
ORCID Icon
Pages 2516-2517 | Received 12 Dec 2016, Accepted 04 Feb 2017, Published online: 28 Feb 2017

References

  • Jabbour EJ, Cortes JE, Kantarjian HM. Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options. Clin Lymphoma Myeloma Leuk. 2013;13:515–529.
  • Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007;8:1018–1029.
  • Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872–884.
  • Lee SE, Choi SY, Bang JH, et al. The long-term clinical implications of clonal chromosomal abnormalities in newly diagnosed chronic phase chronic myeloid leukemia patients treated with imatinib mesylate. Cancer Genet. 2012;205:563–571.
  • Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol. 2002;107:76–94.
  • Savasoglu K, Payzin KB, Ozdemirkiran F, et al. The effect of the additional cytogenetic abnormalities on major molecular response and BCR-ABL kinase domain mutations in long-term follow-up chronic myeloid leukemia patients, a cross sectional study. Leuk Lymphoma. 2016. [Epub ahead of print]. doi: 10.1080/10428194.2016.1265112
  • Fabarius A, Leitner A, Hochhaus A, et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood. 2011;118:6760–6768.
  • Tarkan-Arguden Y, Ar MC, Yılmaz S, et al. Cytogenetic clonal evolution in patients with chronic myeloid leukemia. Biotechnol Biotechnol Equip. 2009;23:1515–1520.
  • Öngören Ş, Tarkan-Argüden Y, Ar MC, et al. Clonal chromosomal abnormalities in Philadelphia-negative cells and their clinical significance in patients with chronic myeloid leukemia: results of a single center. Turkiye Klinikleri J Med Sci. 2009;29:321–330.
  • Bozkurt S, Uz B, Buyukasik Y, et al. Prognostic importance of additional cytogenetic anomalies in chronic myeloid leukemia. Med Oncol. 2013;30:443.
  • Schoch C, Haferlach T, Kern W, et al. Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate. Leukemia. 2003;17:461–463.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.